Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Patriarca

Showing results (41-50 of 156) with videos related to

Pageof 16
Sort By:
Journal of Clinical Medicine|July 27, 2022
Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD)Gabriele Facchin, Chiara Savignano, Marta Lisa Battista, et al.
Haematologica|June 14, 2006
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantationBenedetto Bruno, Francesca Patriarca, Roberto Sorasio, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2011
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. ExperienceFrancesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
Clinical Transplantation|July 17, 2019
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societiesCorrado Girmenia, Tiziana Lazzarotto, Francesca Bonifazi, et al.
Leukemia & Lymphoma|May 4, 2011
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplantFrancesco Spina, Vittorio Montefusco, Claudia Crippa, et al.
Journal of Clinical Medicine|November 19, 2020
Risk Factors and Outcome of <i>C. difficile</i> Infection after Hematopoietic Stem Cell TransplantationChiara Rosignoli, Giuseppe Petruzzellis, Vera Radici, et al.
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Haematologica|August 30, 2008
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2016
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell TransplantationFrancesca Patriarca, Chiara Cigana, Dozzo Massimo, et al.
Blood|September 9, 2011
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantationElena Zamagni, Francesca Patriarca, Cristina Nanni, et al.
Pageof 16

Showing results (41-50 of 156) with videos related to

Sort By:
Pageof 16
Journal of Clinical Medicine|July 27, 2022
Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD)Gabriele Facchin, Chiara Savignano, Marta Lisa Battista, et al.
Haematologica|June 14, 2006
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantationBenedetto Bruno, Francesca Patriarca, Roberto Sorasio, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2011
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. ExperienceFrancesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
Clinical Transplantation|July 17, 2019
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societiesCorrado Girmenia, Tiziana Lazzarotto, Francesca Bonifazi, et al.
Leukemia & Lymphoma|May 4, 2011
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplantFrancesco Spina, Vittorio Montefusco, Claudia Crippa, et al.
Journal of Clinical Medicine|November 19, 2020
Risk Factors and Outcome of <i>C. difficile</i> Infection after Hematopoietic Stem Cell TransplantationChiara Rosignoli, Giuseppe Petruzzellis, Vera Radici, et al.
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Haematologica|August 30, 2008
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2016
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell TransplantationFrancesca Patriarca, Chiara Cigana, Dozzo Massimo, et al.
Blood|September 9, 2011
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantationElena Zamagni, Francesca Patriarca, Cristina Nanni, et al.
Pageof 16